Key references: Oral phosphodiesterase type 5 (PDE5) inhibitors for erectile dysfunction

  • Burnett AL, Nehra A, Breau RH, Culkin DJ, Faraday MM, Hakim LS, et al. Erectile dysfunction: AUA guideline. J Urol 2018;200(3):633–41. https://www.ncbi.nlm.nih.gov/pubmed/29746858
  • Corona G, Rastrelli G, Burri A, Jannini EA, Maggi M. The safety and efficacy of avanafil, a new 2(nd) generation PDE5I: comprehensive review and meta-analysis. Expert Opin Drug Saf 2016;15(2):237–47. https://www.ncbi.nlm.nih.gov/pubmed/26646748
  • Hatzimouratidis K, Giuliano F, Moncado I, Muneer A, Salonia A, Verze P. European Association of Urology (EAU) guidelines male sexual dysfunction. Arnhem, The Netherlands: EAU; 2016. https://uroweb.org/guideline/male-sexual-dysfunction/#3
  • Hatzimouratidis K, Salonia A, Adaikan G, Buvat J, Carrier S, El-Meliegy A, et al. Pharmacotherapy for erectile dysfunction: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med 2016;13(4):465–88. https://www.ncbi.nlm.nih.gov/pubmed/27045254
  • Katz EG, Tan RB, Rittenberg D, Hellstrom WJ. Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility. Ther Clin Risk Manag 2014;10:701–11. https://www.ncbi.nlm.nih.gov/pubmed/25210457
  • Spitzer M, Basaria S, Travison TG, Davda MN, Paley A, Cohen B, et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann Intern Med 2012;157(10):681–91. https://www.ncbi.nlm.nih.gov/pubmed/23165659
  • Tsertsvadze A, Fink HA, Yazdi F, MacDonald R, Bella AJ, Ansari MT, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med 2009;151(9):650–61. https://www.ncbi.nlm.nih.gov/pubmed/19884626